News

Nanobiotix Unveils Promising Results from Phase 1 Study on NBTXR3

Nanobiotix Unveils Promising Results from Phase 1 Study on NBTXR3

Nanobiotix Unveils Promising Results from Phase 1 Study on NBTXR3

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) has recently announced encouraging results from their Phase 1 study investigating JNJ-1900 (NBTXR3) in conjunction with immune checkpoint inhibitors for patients battling primary cutaneous melanoma resistant to anti-PD-1 therapies. This study is particularly significant as it focuses on a challenging population of patients who have exhausted available treatment options.

Key Findings from the Study

The data revealed a favorable safety profile alongside early efficacy signals within a heavily pretreated cohort whose cancer had progressed following multiple therapy lines, including anti-PD-1 treatments. The recommended phase 2 dose for this novel therapy was established at 33% of gross tumor volume (GTV).

Efficacy Metrics

The study reported an impressive best observed objective response rate (ORR) of 47.4% across all lesions, according to RECIST 1.1 criteria. Additionally, a notable disease control rate (DCR) of 78.9% was achieved, highlighting the potential of JNJ-1900 (NBTXR3) in effectively managing tumor response in melanoma patients.

Overall Survival Insights

Patients treated in the study exhibited a median overall survival (mOS) spanning 14.6 months, which adds to the promising nature of this therapy. Investigators of the study concluded that these significant findings warrant further exploration through randomized clinical trials, potentially offering a new treatment alternative for melanoma patients who are either naive or refractory to anti-PD-1 therapies.

Safety and Patient Feasibility

The safety of JNJ-1900 (NBTXR3), combined with immune checkpoint inhibitors like pembrolizumab or nivolumab, was evaluated across all patient responses. Findings indicated that the administration was feasible at the recommended dose, with injection-related adverse events being manageable.

Summary of Safety Profile

Out of the 21 patients involved in the trial, 16 experienced varying degrees of treatment-emergent adverse events (TEAEs), yet the overall therapeutic regimen maintained a favorable safety outlook. Notably, only one patient reported severe side effects classified as grade 3+, underscoring the treatment's potential tolerability.

Future Directions for Nanobiotix

Amidst these encouraging results, Nanobiotix is committed to advancing JNJ-1900 (NBTXR3) through further studies. Chief Medical Officer Louis Kayitalire highlighted the treatment's potential, indicating a relationship between localized tumor response and systemic regression could point towards a re-activation of the immune response in these patients.

Upcoming Conference Call

To disseminate these findings further, Nanobiotix plans to conduct a conference call to discuss this data in detail. Participants can expect insight from CEO Laurent Levy on the implications of these results and future development pathways for JNJ-1900 (NBTXR3).

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) stands out as a first-in-class oncology product utilizing functionalized hafnium oxide nanoparticles. Its innovative mechanism is prompted by radiotherapy, which activates significant tumor cell death, thereby stimulating an adaptive immune response. As this therapy is progressively evaluated across various solid tumor types, promising collaborations are fast-tracking the development of NBTXR3 in congress with existing therapies.

Company Overview

Established in 2003, Nanobiotix is committed to transforming treatment paradigms for patients through pioneering physics-based therapeutic approaches. With a robust patent portfolio, Nanobiotix focuses on advancing therapies that could revolutionize the management of solid tumors and other significant health issues, bolstered by their mission to extend human life possibilities.

Frequently Asked Questions

What are the main findings of the Phase 1 study on JNJ-1900?

The study showed a favorable safety profile and early efficacy signals, with a 47.4% ORR and a 14.6-month median overall survival.

What is the recommended phase 2 dose of JNJ-1900?

The recommended phase 2 dose is established at 33% of the gross tumor volume.

What safety concerns were raised during the study?

Most patients experienced mild to moderate side effects, with only one patient affected by a severe adverse event.

What is the significance of the treatment for melanoma patients?

This treatment offers a potential new option for patients who are resistant to current therapies which significantly broadens treatment avenues.

When will the conference call regarding these findings occur?

The conference call is scheduled for September 18, 2025, at 8:00 AM EDT.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 495

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 0

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 269

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 287

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 399

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 0

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Cryptocurrency Through Sustainable Mining Solutions

Updated Category News Views 132

Ripple and Dogecoin Capture Market Attention Recently, Ripple, known by its trading symbol XRP, regained significant visibility in the cryptocurrency market following a major legal victory against a regulatory body. This resurgence has reignited interest among investors and enthusiasts alike. Meanwhile, Dogecoin has been experiencing a renaissance, driven by the ambitious...

Continue Reading
General Dynamics Sees Growth in Q2 Earnings and Revenue

Updated Category News Views 147

General Dynamics Q2 Financial Highlights General Dynamics reported remarkable financial results for the second quarter of 2025, showcasing a revenue of $13 billion, which marks an 8.9% increase compared to the same quarter last year. The company achieved operating earnings of $1.3 billion, translating to a diluted earnings per share (EPS) of $3.74, reflecting a 14.7%...

Continue Reading
FIU Shines as a Top Public University in New Ranking

Updated Category News Views 77

FIU Ranks High in TIME's New College List Alright, listen up. The latest college buzz isn't just noise—Florida International University (FIU) is sitting pretty at No. 23 among public universities in TIME's first crack at America's Best Colleges for the 2026-2027 term. They're also punching in at No. 62 overall out of 500 schools. For a university that's been...

Continue Reading
Recent Net Asset Value Disclosure for Hargreave Hale AIM VCT

Updated Category News Views 174

Understanding the Latest Net Asset Value Announcement The Hargreave Hale AIM VCT PLC has recently made an important announcement regarding its Net Asset Value (NAV). This provides valuable insights for investors and stakeholders looking to evaluate the fund's performance. It is crucial for those following this investment vehicle to stay informed about NAV updates, as...

Continue Reading
Orvana Minerals Corp. Reports Financial Results for Q1 FY2026

Updated Category News Views 191

Orvana Minerals Corp. Financial Performance Overview TSX:ORV Orvana Minerals Corp. (TSX: ORV) has recently disclosed its financial statements for the first quarter of the fiscal year 2026 through its subsidiary, Empresa Minera Paitití, S.A. (EMIPA). These unaudited results are now available for viewing on the Bolivian stock market. The disclosure marks an important...

Continue Reading